Case Western licenses out nanotechnology to treat bleeding complications

By Jesse Schwartz  
Published: June 6th, 2018

Case Western Reserve University (CWRU) and Haima Therapeutics, a Cleveland-based biotech company, have signed a license agreement for a technology to prevent and treat bleeding complications from trauma, low platelet counts, and surgery.

The nanotechnology, known as SynthoPlate, aims to address the 2 million units of platelets transfused each year in U.S. and the risk of issues such as limited supply, short shelf life, and minimal portability. The innovation can mimic platelets’ abilities to clot at the site of a bleeding injury.

“Outside of large blood banks and trauma centers, platelet products are rarely available,” says Anirban Sen Gupta, a CWRU professor and co-developer of SynthoPlate. “Our nanoparticle technology can be used in civilian and military scenarios of traumatic non-compressible bleeding where donor platelets are not readily available. This has been the motivation behind the research on platelet surrogates in my laboratory, and SynthoPlate is a technology that stemmed from it.”

The license agreement with Haima Therapeutics was managed through CWRU’s Technology Transfer Office. It will enable pre-clinical testing of the technology, including safety profiling and the feasibility of scaled up manufacturing.

“We are excited to work with Dr. Sen Gupta to advance this highly promising technology toward the clinic,” says Christa Pawlowski, co-founder and chief science officer at Haima. “Our goal is to provide a product that can address the real, unmet needs of patients with bleeding complications.”

Source: Crain’s Cleveland Business